mFOLFIRI

DRUG3 trials

Sponsors

Peking University, Pancreatic Cancer Research Team, University of Utah

Conditions

Advanced Esophageal CarcinomaAppendiceal CancerColorectal CancerPeritoneal CarcinomaStage IV Pancreatic Cancer

Phase 1

Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

CompletedNCT01488552

Pancreatic Cancer Research TeamStage IV Pancreatic Cancer

Start: 2011-11-30End: 2016-08-31Updated: 2016-08-18

Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer

TerminatedNCT04158349

University of UtahAppendiceal Cancer, Colorectal Cancer, Peritoneal Carcinoma

Start: 2021-03-22End: 2021-05-14Updated: 2021-09-27

Phase 2

mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical Trial

Peking UniversityAdvanced Esophageal Carcinoma

Start: 2009-05-31End: 2012-06-30Target: 50Updated: 2010-01-07

Related Papers

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Journal of Visualized Experiments2015-06-2027 citations

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Journal of Visualized Experiments2015-06-203 citations

Phase II study of nab-paclitaxel/gemcitabine (NabP-Gem) alternating with FOLFIRI as 1st line therapy ( Rx) in patients (pts) with metastatic pancreatic cancer (mPC).

Journal of Clinical Oncology2015-05-20

Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer.

Journal of Clinical Oncology2014-01-209 citations